| Autor: |
Bidère, Nicolas, Ngo, Vu N., Lee, Jeansun, Collins, Cailin, Zheng, Lixin, Wan, Fengyi, Davis, R. Eric, Lenz, Georg, Anderson, D. Eric, Arnoult, Damien, Vazquez, Aimé, Sakai, Keiko, Zhang, Jun, Meng, Zhaojing, Veenstra, Timothy D., Staudt, Louis M., Lenardo, Michael J. |
| Předmět: |
|
| Zdroj: |
Nature; 3/5/2009, Vol. 458 Issue 7234, p92-96, 5p, 4 Graphs |
| Abstrakt: |
The transcription factor NF-κB is required for lymphocyte activation and proliferation as well as the survival of certain lymphoma types. Antigen receptor stimulation assembles an NF-κB activating platform containing the scaffold protein CARMA1 (also called CARD11), the adaptor BCL10 and the paracaspase MALT1 (the CBM complex), linked to the inhibitor of NF-κB kinase complex, but signal transduction is not fully understood. We conducted parallel screens involving a mass spectrometry analysis of CARMA1 binding partners and an RNA interference screen for growth inhibition of the CBM-dependent ‘activated B-cell-like’ (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). Here we report that both screens identified casein kinase 1α (CK1α) as a bifunctional regulator of NF-κB. CK1α dynamically associates with the CBM complex on T-cell-receptor (TCR) engagement to participate in cytokine production and lymphocyte proliferation. However, CK1α kinase activity has a contrasting role by subsequently promoting the phosphorylation and inactivation of CARMA1. CK1α has thus a dual ‘gating’ function which first promotes and then terminates receptor-induced NF-κB. ABC DLBCL cells required CK1α for constitutive NF-κB activity, indicating that CK1α functions as a conditionally essential malignancy gene—a member of a new class of potential cancer therapeutic targets. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
